M
MOC
vs
W
WIG20
Over the past 12 months, MOC has underperformed WIG20, delivering a return of -31% compared to the WIG20's +42% growth.
Stocks Performance
MOC vs WIG20
Performance Gap
MOC vs WIG20
Performance By Year
MOC vs WIG20
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Molecure SA
Glance View
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.